Moderna Inc. shares surged Wednesday in premarket trading following positive results from a late-stage trial of its personalized mRNA cancer vaccine [1, 2].
The results mark the first successful late-stage study for an mRNA-based cancer therapy. This development suggests that the technology used for COVID-19 vaccines could be pivoted to treat various forms of malignancy.
The experimental vaccine, developed in partnership with Merck & Co., was designed to reduce the recurrence of melanoma [1, 2]. Clinical data indicates the therapy helped cut the likelihood that the cancer would return in patients participating in the study [1, 2].
Investor reaction was immediate and volatile. Reports on the exact magnitude of the stock's climb vary across financial news outlets. Yahoo Finance reported an 85% increase in premarket trading [2], while its own headline suggested a 95% increase [2]. Forbes reported a 93% increase, which brought the share price to approximately $121.90 [1].
Other summaries indicated the surge exceeded 120% [RSS], with some headlines claiming as much as 125% [YouTube]. The discrepancy likely reflects the rapid fluctuations of premarket pricing before the official opening of the U.S. stock markets.
Moderna has focused heavily on personalized medicine, where vaccines are tailored to the specific genetic mutations of a patient's tumor. This approach aims to prime the immune system to recognize and attack remaining cancer cells after a primary tumor has been surgically removed.
While the trial showed success in reducing recurrence, the company has not yet released the full dataset regarding long-term survival rates. The partnership with Merck & Co. remains central to the vaccine's clinical rollout and potential regulatory submission.
“The results mark the first successful late-stage study for an mRNA-based cancer therapy.”
The success of this trial validates the use of mRNA technology beyond infectious diseases, potentially opening a new frontier in oncology. By creating personalized treatments tailored to individual tumors, Moderna and Merck are moving toward a 'precision medicine' model that could significantly improve outcomes for melanoma patients and provide a blueprint for treating other solid tumors.
